

**LAHIVE  
&  
COCKFIELD**  
LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DIACONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. MANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DOANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINIC, Ph.D.  
DAVID J. RICKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICHARD MAND  
MICHAEL PHILLIPPS  
LISA M. DIROCCO  
MATHAWAY P. RUSSELL  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
PETER A. DIMATTIA  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
SIBILEY P. REPPERT

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
DANIEL B. KO

TECHNICAL SPECIALISTS  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
EUNHOON LEE  
ALLAN JAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Admitted in TX only

# Facsimile Cover Sheet

FAX RECEIVED  
AUG 26 2002  
GROUP 1600

To: Gabriele E. Bugaisky, Ph.D.  
Company: United States Patent & Trademark Office  
Location: Washington, D.C.  
Phone: (703)308-4201  
Fax: (703)305-3014

OFFICIAL

From: Maria Laccotripe  
Zacharakis, Ph.D.  
Phone: (617) 227-7400  
Fax: (617) 742-4214  
Case No.: USSN: 09/174,937  
Atty. Dkt. No.: MNI-061RCE

Date: 08/23/02  
Sent By: JMS:mxh  
Pages including this  
cover page: 19

Message:

Please **ENTER AND DELIVER** to Examiner  
Bugaisky at Group Art Unit 1653.

The documents transmitted by this facsimile are intended for the use of the individual or the entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of the message is not the intended recipient, or the employee or agent responsible for delivering this document to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original facsimile to us at the above address via the U.S. Postal Service. Thank you.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/174,937
Filing Date	October 19, 1998
First Named Inventor	Rory A.J. Curtis
Group Art Unit	1653
Examiner Name	Bugaisky, G.
Attorney Docket No.	MNI-061RCE

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Request for Five-Month Extension of Time

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months. Fee under 37 CFR 1.17(i) required)
- b. ☒ Other Certificate of Limited Recognition Under 37 CFR §10.9(b)

## 3. Fees

The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 12-0080
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Mana Laccotripe Zacharakis, Ph.D.	Registration No. (Attorney/Agent)	Limited Recognition Under 37 CFR §10.9(b)
Signature	<i>Mana Laccotripe</i>	Date	August 23, 2002

## Certificate of Facsimile Transmission

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, Box RCE, Washington, D.C. 20231 on the date set forth below.

By:

*Mana Laccotripe*  
Maria Laccotripe Zacharakis, Ph.D.  
Attorney for Applicant  
Limited Recognition Under 37 C.F.R. 10.9(b)

09/05/2002 09:12:11 00000003 120080 09174937  
Sale Ref: 00000003 DHH: 120080 09174937  
01 FC:128 1040.00 CH

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of: Rory A.J. Curtis and M.  
Alexandra Glucksmann

RCE of Serial No.: 09/174,937

Filed: October 19, 1998

For: *ISOLATED PROTEINS AND NUCLEIC ACID  
MOLECULES HAVING HOMOLOGY TO THE NIP2  
PROTEIN AND USES THEREOF*

Attorney Docket No.: MNI-061RCE

Group Art Unit: 1653

Examiner: Gabriele E. Bugaisky, Ph.D.

Commissioner for Patents  
Box RCE  
Washington, D.C. 20231

**Certificate of Facsimile Transmission**

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents,  
Box RCE, Washington, D.C. 20231 on the date set forth below.

By:

August 23, 2002  
Date of Signature

*LAHOTRIPE*  
Maria Laccotripe Zacharakis, Ph.D.  
Attorney for Applicant  
Limited Recognition Under 37 C.F.R. 10.9(b)

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to examination of the above-identified patent application, please amend the  
application as follows.

In the Specification:

Please replace lines 3-10 at page 10 with:

*E1*  
*F1*  
--In another embodiment, a NIP2b, NIP2cL, and NIP2cS of the present invention is  
identified based on the presence of a "calcium-binding domain" in the protein or corresponding  
nucleic acid molecule. As used herein, the term "calcium-binding domain" includes a protein